Dean J. Naylor
Corporate Officer/Principal chez The University of Queensland
Profil
Dean J.
Naylor is currently a Principal at The University of Queensland.
Prior to this, he was a Principal at the University of Adelaide and Head-Intellectual Property Development at CBio Ltd.
Postes actifs de Dean J. Naylor
| Sociétés | Poste | Début |
|---|---|---|
| The University of Queensland | Corporate Officer/Principal | - |
Anciens postes connus de Dean J. Naylor
| Sociétés | Poste | Fin |
|---|---|---|
| University of Adelaide | Corporate Officer/Principal | - |
CBio Ltd.
 CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
CBio Ltd.
CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia. | Health Technology |